Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem...
– Conference Call Today at 4:30 p.m. ET
Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference...
SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
– Permanent, product-specific J-code facilitates efficient claims and reimbursement –
– Conference Call Today at 4:30 p.m. ET
Barchart Research What to Expect from OMER Earnings OMER Generated March 30, 2026 Current Price $9.81 EPS Estimate $-0.55 Consensus Rating Moderate Buy Average Move 18.93% Omeros Burns Cash While Everyone...
Barchart Research What to Expect from OMER Earnings OMER Generated March 27, 2026 Current Price $9.88 EPS Estimate $-0.55 Consensus Rating Moderate Buy Average Move 18.93% Omeros Has Been Quietly Burning...